Financial Report: Novo Nordisk FY Revenues: $21.4 billion (+11%) FY Earnings: $7.3 billion (+13%) Comments: Operating profit increased by 8% in to $8.9 billion. Sales in International Operations increased by 12%, with sales in North America up 10%. Sales within Diabetes and Obesity care increased by 13% to $18.5 billion, driven by GLP-1 sales growth of 28% reflecting the uptake of Ozempic and Rybelsus. Obesity care sales (Saxenda and Wegovy) grew 50% to $1.3 billion and Biopharm sales increas...